Amicus Therapeutics

Yahoo Finance • 9 days ago

All J.P. Morgan's top stock picks for 2026

[Countdown to 2026. Loading year from 2025 to 2026. New year start concept.] SmileStudioAP J.P. Morgan identifies specific traits that define their Best Ideas for 2026. These companies typically possess: * Strong Financial Health: Rob... Full story

Yahoo Finance • 11 days ago

Noteworthy ETF Inflows: XBI, FOLD, MRNA, EXEL

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $218.7 million dollar inflow -- that... Full story

Yahoo Finance • 14 days ago

Catalyst Watch: Defense stocks in play, FOMC minutes, and opening 2026 trades

[Wall Street New York Stock Exchange Stock Market & Government Tariffs] Douglas Rissing Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may i... Full story

Yahoo Finance • 16 days ago

Assessing Amicus Therapeutics (FOLD) Valuation After Its Recent Share Price Rally

Amicus Therapeutics (FOLD) has been quietly rewarding patient holders, with the stock climbing around 44% over the past month and more than 70% in the past 3 months, outpacing many biotech peers. See our latest analysis for Amicus Therape... Full story

Yahoo Finance • 18 days ago

BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push

BioMarin Pharmaceutical has agreed to buy rare disease biotech Amicus Therapeutics, adding three approved or late-stage lysosomal storage disorder therapies to its portfolio. Under the terms of the agreement, BioMarin will pay cash for al... Full story

Yahoo Finance • 20 days ago

Key deals this week: Trump Media & Technology, Howard Hughes, BioMarin Pharmaceutical and more

[Documents about mergers and acquisitions m&a with a pen.] designer491 Here's a list of key deals reported across sectors this week: * BioMarin Pharmaceutical (BMRN [https://seekingalpha.com/symbol/BMRN]) has agreed to acquire [https:/... Full story

Yahoo Finance • 20 days ago

BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus

We recently published 10 Firms in the Limelight. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best performers on Friday. BioMarin Pharmaceutical extended its winning streak to a third straight day on Friday, surging 17.71 perc... Full story

Yahoo Finance • 20 days ago

Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger

We recently published 10 Firms in the Limelight. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best performers on Friday. Amicus Therapeutics soared to a new 52-week high on Friday, jumping 30.21 percent to close at $14.18 apiece... Full story

Yahoo Finance • 20 days ago

Investing.com’s stocks of the week

Investing.com -- It’s been a mixed week for equities, with the rise so far in Friday’s session putting the S&P on track to close flat for the week, while the Nasdaq would post a 0.2% increase. Here are our stocks of the week: Micron Mic... Full story

Yahoo Finance • 21 days ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change ProPhase Labs Inc. 221,499,940 0.1839 0.1376 0.1414 +0.0363 Inspire Vete... Full story

Yahoo Finance • 27 days ago

Amicus Therapeutics (FOLD) Soars to 52-Week High on ‘Strong Buy’ Reco

We recently published 10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best performers on Friday. Amicus jumped to a new 52-week high on Friday, as investors took heart... Full story

Yahoo Finance • last month

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Insti... Full story

Yahoo Finance • 2 months ago

Amicus targets $1B combined sales by 2028 as Galafold and Pompe therapies drive record growth

Earnings Call Insights: Amicus Therapeutics (FOLD) Q3 2025 MANAGEMENT VIEW * Bradley Campbell, CEO, highlighted another quarter of double-digit revenue growth in the Fabry and Pompe core business, stating, “Galafold delivered 13% year-... Full story

Yahoo Finance • 3 months ago

Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story

Yahoo Finance • 3 months ago

Peek Under The Hood: VB Has 14% Upside

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 4 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index adding 0.3% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Target initiated, Nike upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: RBC Capital upgraded Nike (NKE) to Out... Full story

Yahoo Finance • 4 months ago

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) st... Full story

Yahoo Finance • 4 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Cantor Global Healthcar... Full story

Yahoo Finance • 5 months ago

Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading

Amicus Therapeutics Inc (NASDAQ:FOLD [https://www.chartmill.com/stock/quote/FOLD]) reported second-quarter 2025 financial results, delivering revenue and earnings per share (EPS) that exceeded analyst expectations. The company's performanc... Full story